Nasal Insulin IND
Executive Summary
California Biotechnology Inc. receives FDA approval for Phase I clinical testing on Nazlin, nasally administered insulin. The insulin product is the first to reach the IND stage for Cal Bio. Lilly has a letter of intent to develop and market the nasal formulation. Cal Bio Chairman William Baker commented that Cal Bio expects "to conclude commercial arrangements with Lilly on licensing of our Nazdel technology with insulin" following completion of Phase I work.